Skip to main content
Publications
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M , Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo . Poster presented at the 35th Anniversary Fall Clinical Dermatology Conference; October 23, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Zheng S, D'Souza VK , Bartis D, Dancer RC, Parekh D, Naidu B, Gao-Smith F, Wang Q, Jin S, Lian Q, Thickett DR. Lipoxin A4 promotes lung epithelial repair whilst inhibiting fibroblast proliferation . ERJ Open Res. 2016 Oct 3;2(3). doi: 10.1183/23120541.00079-2015
Taylor S, Demeyin (Nuabor) W , Muls A, Ferguson C, Farnell DJ, Cohen D, Andreyev J, Green J, Smith L, Ahmedzai S, Pickett S, Nelson A, Staffurth J. Improving the well-being of men by Evaluating and Addressing the Gastrointestinal Late Effects (EAGLE) of radical treatment for prostate cancer: study protocol for a mixed-method implementation project . BMJ Open. 2016 Oct 3;6(10):e011773. doi: 10.1136/bmjopen-2016-011773
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M , Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo . Poster presented at the Maui Derm NP+ PA Fall 2016; September 29, 2016. Asheville, NC. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Gottlieb AB, Pariser D, Tsai TF, Pinter A, Zhou Y, Gilloteau I, Mordin M , Davenport E , Guana A, Reich K. Secukinumab provides greater 52-week sustained relief in dermatology-specific quality-of-life impact than ustekinumab . Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Puig L, Sofen H, Augustin M, Abramovits W, Kingo K, Gilloteau I, Zhao Y, Mordin M , Williams N, Guana A, Korman N. Secukinumab provides greater 52-week improvements in patient-reported outcomes versus ustekinumab in patients with moderate to severe psoriasis . Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Lebwohl M, Blauvelt A, Augustin M, Zhao Y, Gilloteau I, Herrera V, Milutinovic M, You R, Mordin M , McLeod L , Strober B. Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling . Poster presented at the 2016 AAD Summer Meeting; July 2016. Boston, MA.
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M , Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1049
Bartis D, Crowley LE, D'Souza VK , Borthwick L, Fisher AJ, Croft AP, Pongracz JE, Thompson R, Langman G, Buckley CD, Thickett DR. Role of CD248 as a potential severity marker in idiopathic pulmonary fibrosis . BMC Pulm Med. 2016 Apr 14;16(1):51. doi: 10.1186/s12890-016-0211-7
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Herrera V, Mordin M , Odom D , Papavassilis C, Nyirady J, Lebwohl M. Secukinumab provides clearer skin and better control on patient-reported psoriasis symptoms of itching, pain, and scaling than placebo and etanercept . J Psoriasis and Psoriatic Arthritis. 2016;1(4):167-75.
Dancer RC, Parekh D, Lax S, D'Souza V , Zheng S, Bassford CR, Park D, Bartis DG, Mahida R, Turner AM, Sapey E, Wei W, Naidu B, Stewart PM, Fraser WD, Christopher KB, Cooper MS, Gao F, Sansom DM, Martineau AR, Perkins GD, Thickett DR. Vitamin D deficiency contributes directly to the Acute Respiratory Distress Syndrome (ARDS) . Thorax. 2015 Jul;70(7):617-24. doi: 10.1136/thoraxjnl-2014-206680
Mahida SR , Seoane E, Klinger E, Salazar A, HER QL, Medoff J, Amato M, Dykes PC, Haas J, Bates D, Schiff G. Cost of reporting possible adverse drug reactions in medical outpatients using a telephonic interactive voice response system . Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 20, 2015. Philadelphia, PA. [abstract] Value Health. 2015 May 1; 18(3):PA257. doi: 10.1016/j.jval.2015.03.1498
Police RL, Trask PC, Wang J, Olivares R, Khan SB , Abbe A, Colosia AD , Njue AI , Sherrill EH, Ruiz-Soto R, Kaye JA, Hamadani M. Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis . Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):199-207. doi: 10.1016/j.clml.2014.09.008
Njue A , Colosia A , Trask PC, Olivares R, Khan S , Police R, Abbe A, Wang J, Kaye JA, Ruiz-Soto R, Awan F. Clinical efficacy and safety in relapsed/refractory mantle cell lymphoma: a systematic literature review . Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):1-12. doi: 10.1016/j.clml.2014.03.006
Colosia A , Njue A , Trask PC, Olivares R, Khan S , Abbe A, Police R, Wang J, Ruiz-Soto R, Kaye JA, Awan F. Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review . Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):343-55. doi: 10.1016/j.clml.2014.02.012